Therapies of the future – where are we heading?
This is the title of Philip Gregory's key note at the BioEntrepreneurship Summit on 10/11. October in Munich. Philip D. Gregory has served as Chief Scientific Officer of bluebird bio since June 2015, a US biotech company focused on gene therapy, cancer immunotherapy and genome editing.
Philip Gregory has led pioneering research in gene therapy and genome editing and was named by Thompson Reuters as one of “The World’s Most Influential Scientific Minds 2014” and “Most Cited Researchers 2015”.
In his speech, Philip Gregory will share both his scientific and entrepreneurial expertise with you as innovative life sciences start-up or SME.
Be there and follow Gregory's presentation with his experiences and visions - sign up now at BioEntrepreneurship Summit.
Prior to his career in the industry, Gregory studied the role of chromatin structure in gene regulation at the LMU in Munich as a postdoc. So it will be almost like a home game for him.
More about his profile and of the other speakers at the Summit you can find here: www.bioentrepreneurshipsummit.org/speakers.html